Search Results - "Kolb, E. A."

Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer by Mills, Christopher C, Kolb, E A, Sampson, Valerie B

“…This review describes the pivotal roles of cell-cycle and checkpoint regulators and discusses development of specific cell-cycle inhibitors for therapeutic use…”
Get full text

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy by Mills, Christopher C, Kolb, E A, Sampson, Valerie B

“…Preclinical and clinical development of agents that inhibit cell-cycle progression have brought an understanding of the feasibility of targeting various…”
Get full text

An Insight into the Role of Mesothelin in Pediatric Acute Myeloid Leukemia by Faust, Joshua R., Hamill, Darcy, Kolb, E. A., Gopalakrishnapillai, Anilkumar, Barwe, Sonali P.

“…Pediatric acute myeloid leukemia (AML) is characterized by the malignant transformation of hematopoietic stem and progenitor cells that lead to the…”
Get full text

p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma by Currier, Arthur W., Kolb, E. A., Gorlick, Richard G., Roth, Michael E., Gopalakrishnan, Vidya, Sampson, Valerie B.

“…The p27/kip1 (p27) tumor suppressor inhibits cyclin/cyclin-dependent kinase (CDK) complexes and halts cell cycle progression. p27 further regulates invasion…”
Get full text

The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis by Vetter, Nancy S, Kolb, E A, Mills, Christopher C, Sampson, Valerie B

“…MicroRNA-34a (miR-34a) is a master regulator of signaling networks that maintains normal physiology and disease and is currently in development as a…”
Get full text

A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia by KOLB, E. A, STEINHERZ, P. G

“…We report the results of a phase 2 nonrandomized single-arm trial of a combination therapy for relapsed or refractory leukemia. From January 1999 to June 2002,…”
Get full text

P518: PEDAL/EUPAL INTERNATIONAL COLLABORATION TO IMPROVE THE OUTCOME OF CHILDREN WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA by Ceolin, V., Ishimaru, S., Bautista, F., Goemans, B., Kolb, E. A., Di Laurenzio, L., Cooper, T. M., Bakker, M., Wahlstrom, J., Sunkersett, G., Ku, G., Zwaan, C., Reinhardt, D., Nichols, G.

Get full text

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma by Laverdiere, Caroline, Kolb, E. Anders, Supko, Jeffrey G., Gorlick, Richard, Meyers, Paul A., Maki, Robert G., Wexler, Leonard, Demetri, George D., Healey, John H., Huvos, Andrew G., Goorin, Allen M., Bagatell, Rochelle, Ruiz‐Casado, Ana, Guzman, Cecilia, Jimeno, Jose, Harmon, David

“…BACKGROUND Recurrent osteosarcoma is a drug‐resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of…”
Get full text

Vibrio fluvialis : An underrecognized enteric pathogen in infants? by KOLB, E. A, EPPES, S. C, KLEIN, J. D

“…We report a case of Vibrio fluvialis gastroenteritis in an infants 3 1/2 weeks old. The case was unusual because no likely epidemiologic risk factors were…”
Get full text

Abstract 1952: Epigenetic modifiers outperform chemotherapy in prolonging survival in patient-derived xenograft models of Down syndrome AML by Barwe, Sonali P., Kolb, E A., Gopalakrishnapillai, Anilkumar

“…Abstract Children with Down syndrome (DS) are at a 500-fold increased risk for developing acute myeloid leukemia (AML) before they reach five years of age…”
Get full text

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration by Pearson, Andrew D J, Zwaan, C Michel, Kolb, E Anders, Karres, Dominik, Guillot, Julie, Kim, Su Young, Marshall, Lynley, Tasian, Sarah K, Smith, Malcolm, Cooper, Todd, Adamson, Peter C, Barry, Elly, Benettaib, Bouchra, Binlich, Florence, Borgman, Anne, Brivio, Erica, Capdeville, Renaud, Delgado, David, Faller, Douglas, Fogelstrand, Linda, Fraenkel, Paula Goodman, Hasle, Henrik, Heenen, Delphine, Kaspers, Gertjan, Kieran, Mark, Klusmann, Jan-Henning, Lesa, Giovanni, Ligas, Franca, Mappa, Silvia, Mohamed, Hesham, Moore, Andrew, Morris, Joan, Nottage, Kerri, Reinhardt, Dirk, Scobie, Nicole, Simko, Stephen, Winkler, Thomas, Norga, Koen, Reaman, Gregory, Vassal, Gilles

“…The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40%…”
Get full text

Review: Recent advances of cell cycle inhibitor therapies for pediatric cancer by Mills, Christopher C., Kolb, EA, Sampson, Valerie B.

“…This review describes the pivotal roles of cell cycle and checkpoint regulators and discusses development of specific cell cycle inhibitors for therapeutic use…”
Get full text

Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A by Smith, M. A., Morton, C. L., Carol, H., Gorlick, R. G., Kang, M. H., Keir, S. T., Kolb, E. A., Lock, R. B., Maris, J. M., Houghton, P. J.

“…Abstract only 10015 Background: GSK923295A is a small molecule inhibitor of centromere-associated protein E (CENP-E), a mitotic kinesin that is required for…”
Get full text

Dickkopf 3 inhibits invasion and motility of saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway by HOANG, Bang H, KUHO, Tadahiko, HEALEY, John H, RUI YANG, NATHAN, Saminathan S, KOLB, E. Anders, MAZZA, Bethanne, MEYERS, Paul A, GORLICK, Richard

“…Osteosarcoma (OS) is a primary malignancy of bone with a tendency to metastasize early. Despite intensive chemotherapy and surgical resection, approximately…”
Get full text

Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG by Smith, M. A., Maris, J. M., Keir, S. T., Lock, R. B., Carol, H., Gorlick, R., Kolb, E. A., Keshelava, N., Reynolds, C. P., Morton, C., Houghton, P. J.

“…Abstract only 3575 Background: 17-DMAG is a small-molecule inhibitor of the protein chaperone HSP90 that is being developed as an anticancer agent because of…”
Get full text

Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia by BERKOWITZ, Richard L, KOLB, E. Anders, MCFARLAND, Janice G, WISSERT, Megan, PRIMANI, Andrea, LESSER, Martin, BUSSEL, James B

“…Antenatal therapy with intravenous immunoglobulin (IVIG) and prednisone has been shown to improve fetal thrombocytopenia and reduce the incidence of…”
Get full text

Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults by KOLB, E. Anders, KUSHNER, Brian H, WOLDEN, Suzanne, MEYERS, Paul A, GORLICK, Richard, LAVERDIERE, Caroline, HEALEY, John H, LAQUAGLIA, Michael P, HUVOS, Andrew G, JING QIN, HA THANH VU, WEXLER, Leonard

“…To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. P6 was a prospective…”
Get full text

Ecteinascidin-743 inhibits activated but not constitutive transcription by FRIEDMAN, Debbie, ZHEN HU, KOLB, E. Anders, GORFAJN, Barbara, SCOTTO, Kathleen W

“…Ecteinascidin-743 (ET-743) is a promising chemotherapeutic agent currently in Phase III clinical trials. Previous studies indicated a novel spectrum of…”
Get full text

Imatinib mesylate in Philadelphia chromosome‐positive leukemia of childhood by Kolb, E. Anders, Pan, Qiulu, Ladanyi, Marc, Steinherz, Peter G.

“…BACKGROUND Initial treatment for adult patients with Philadelphia chromosome‐positive (Ph[+]) chronic myelogenous leukemia (CML) now includes imatinib…”
Get full text

Early Passengers to Virginia: When Did They Really Arrive? by Kolb, Avery E

Get full text